You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 159 No. 4, February 22, 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (51)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis

Melanie M. van der Klauw, MD, PhD; Robert Goudsmit, MD, PhD; M. Ruud Halie, MD, PhD; Mars B. van't Veer, MD, PhD; Ron M. C. Herings, PharmD, PhD; J. H. Paul Wilson, MD; Bruno H. Ch. Stricker, MB, PhD

Arch Intern Med. 1999;159:369-374.

Background  Agranulocytosis is a life-threatening disorder, often caused by drugs. Incidences or risks of drug-induced agranulocytosis are not well known, since it is rare.

Methods  To determine the risk of drug-associated agranulocytosis as a reason for admission to Dutch hospitals, we performed a population-based case-cohort study. Hospital discharge data came from the Dutch Centre for Health Care Information, Utrecht, which contains data on all general and university hospitals in the Netherlands. The reference cohort consisted of all persons in the catchment area of the Pharmaco Morbidity Record Linkage System (PHARMO RLS) in the Netherlands, composing a population of approximately 220,000 to 484,000 persons from 1987 through 1990. All admissions during that period with agranulocytosis or related diagnoses were included in the study (n=923). The potential causes of agranulocytosis were assessed in all cases classified as probable or possible agranulocytosis.

Results  Discharge summaries were received of 753 admissions, of which 678 contained enough information for analysis. Of the 678, 108 were classified as "agranulocytosis probable" or as "agranulocytosis possible." In 75 of these 108 cases, agranulocytosis had been the reason for admission. Fifteen patients had used methimazole within 10 days before developing agranulocytosis; 2, carbimazole; 9, sulfasalazine; 8, sulfamethoxazole-trimethoprim; 4, clomipramine hydrochloride; and 2, dipyrone with analgesics, yielding adjusted relative risks of agranulocytosis of 114.8 (for thyroid inhibitors combined) (95% confidence interval [CI], 60.5-218.6), 74.6 (95% CI, 36.3-167.8), 25.1 (95% CI, 11.2-55.0), 20.0 (95% CI, 6.1-57.6), and 26.4 (95% CI, 4.4-11.1), respectively.

Conclusions  The highest relative risks were found for thyroid inhibitors, sulfamethoxazole-trimethoprim, sulfasalazine, clomipramine, and dipyrone combined with analgesics.


From the Departments of Internal Medicine II (Drs van der Klauw and Wilson) and Epidemiology and Biostatistics (Dr Stricker), Erasmus University Medical School, Rotterdam; Drug Safety Unit, Inspectorate for Health Care, Rijswijk, Amsterdam (Drs van der Klauw and Stricker); Department of Hematology, University Hospital Groningen, Groningen (Dr Halie); Department of Hematology, Dr Daniel den Hoed Cancer Centre, Rotterdam (Dr van't Veer); and Department of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht, Utrecht (Dr Herings), the Netherlands. Dr Goudsmit is in private practice in Amsterdam.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Drug-Associated Agranulocytosis: Experience at Strasbourg Teaching Hospital
Andrès Emmanuel and Frédéric Maloisel
Arch Intern Med. 1999;159(19):2366-2367.
EXTRACT | FULL TEXT  

Drug-Induced Allergic Cytopenia: In Vitro Confirmation by the Lymphocyte Transformation Test
Bernhardt Sachs, Stephan Erdmann, Iris Borchardt, Peter Drüke, Hans Friedrich Merk, and Jan Palmblad
Arch Intern Med. 2000;160(14):2218-2219.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Agranulocytosis Induced by Nonchemotherapy Drugs
Andersohn et al.
ANN INTERN MED 2008;148:320-321.
FULL TEXT  

Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs
Andersohn et al.
ANN INTERN MED 2007;146:657-665.
ABSTRACT | FULL TEXT  

Myeloid disorders
Link and Wun
ASH-SAP 2007;2007:143-171.
FULL TEXT  

Population-Based Drug-Induced Agranulocytosis
Ibanez et al.
Arch Intern Med 2005;165:869-874.
ABSTRACT | FULL TEXT  

Congenital and Acquired Neutropenia
Berliner et al.
ASH Education Book 2004;2004:63-79.
ABSTRACT | FULL TEXT  

Prednisone-induced neutropenia after cadaveric kidney transplantation
Schaub et al.
Nephrol Dial Transplant 2002;17:1119-1121.
FULL TEXT  

Antibiotic-Induced Agranulocytosis: A Monocentric Study of 21 Cases
Andres and Maloisel
Arch Intern Med 2001;161:2619-2619.
FULL TEXT  

Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis
Andres et al.
QJM 2001;94:423-428.
ABSTRACT | FULL TEXT  

Cyclosporin for sulphasalazine-induced aplastic anaemia in a patient with early rheumatoid arthritis
Nurmohamed et al.
Rheumatology (Oxford) 2000;39:1431-1433.
FULL TEXT  

Drug-Induced Allergic Cytopenia: In Vitro Confirmation by the Lymphocyte Transformation Test
Sachs et al.
Arch Intern Med 2000;160:2218-2219.
FULL TEXT  

Drug-Induced Neutropenias: Now and Then
Palmblad et al.
Arch Intern Med 1999;159:2745-2745.
FULL TEXT  

Drug-Associated Agranulocytosis: Experience at Strasbourg Teaching Hospital
Emmanuel and Maloisel
Arch Intern Med 1999;159:2366-2367.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.